Due to health issues, this site is no longer maintained and will be shut down shortly.

NVNOW enVVeno Medical Corporation - Warrants

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based devices to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and works as a replacement venous valve to reduce reflux and venous hypertension, as well as to restore proper directional blood flow back to the heart. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.  This security was issued by enVVeno Medical Corporation , whose common stock symbol is NVNO.

$0.05  -0.01 (-14.83%)
As of 03/22/2023 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Warrants
Category3:  Operating Companies
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  USA
Country of incorporation:  
IPO date:  05/31/2018
Outstanding shares:  1,142,857
Average volume:  2,009
Market cap:   $46,412,800
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy